Becton, Dickinson and Company (NYSE:BDX) EVP Sells $14,509.92 in Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 74 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $196.08, for a total value of $14,509.92. Following the transaction, the executive vice president directly owned 16,506 shares of the company’s stock, valued at $3,236,496.48. The trade was a 0.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Michael Feld also recently made the following trade(s):

• On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $193.36, for a total transaction of $14,502.00.
• On Monday, October 27th, Michael Feld sold 57 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $186.01, for a total transaction of $10,602.57.

Becton, Dickinson and Company Stock Down 0.0%

BDX stock opened at $196.11 on Monday. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The business has a fifty day moving average price of $190.37 and a 200-day moving average price of $186.37. The stock has a market capitalization of $55.87 billion, a P/E ratio of 33.70, a P/E/G ratio of 1.81 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company had revenue of $5.32 billion during the quarter. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Analysts Set New Price Targets

BDX has been the subject of a number of research analyst reports. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Jefferies Financial Group upped their price target on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Stifel Nicolaus decreased their price objective on Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Piper Sandler cut their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Finally, Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Four investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $205.64.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of Becton, Dickinson and Company during the first quarter valued at about $321,000. CreativeOne Wealth LLC lifted its stake in shares of Becton, Dickinson and Company by 13.8% in the first quarter. CreativeOne Wealth LLC now owns 2,992 shares of the medical instruments supplier’s stock worth $685,000 after acquiring an additional 362 shares in the last quarter. WPG Advisers LLC acquired a new stake in Becton, Dickinson and Company during the 1st quarter valued at approximately $36,000. Finally, Vident Advisory LLC boosted its stake in Becton, Dickinson and Company by 185.8% during the 1st quarter. Vident Advisory LLC now owns 11,082 shares of the medical instruments supplier’s stock valued at $2,539,000 after acquiring an additional 7,204 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.